WAYNE, Pa., May 10, 2011 /PRNewswire/ — Pierrel Research USA,
Inc. (www.pierrel-research-usa.com),
a subsidiary of Pierrel SpA, the Italian-based, global
pharmaceutical services company (www.pierrel.it), announces the US
launch of Orabloc™ (Articaine hydrochloride 4% with
epinephrine 1:100,000 and Articaine hydrochloride 4% with
epinephrine 1:200,000). Orabloc is a new purer formulation of
Articaine with epinephrine, an injectable dental anesthetic for
routine dental procedures and oral surgery.
“With the availability of Orabloc, US dentists will now have
a purer choice in Articaine anesthetics,” said Canio Mazzaro,
Chairman, and CEO of Pierrel SpA. “Up to this point, all
available US brands of Articaine are manufactured in Canada using
the terminal sterilization method. Pierrel manufactures Orabloc
using an aseptic method in our FDA-approved facility in Capua,
Italy and the result is a purer formulation of Articaine. Orabloc
is an Articaine with less degradation products and
impurities such as articaine acid and epinephrine sulphonic acid.
What’s more, Orabloc requires less overage of epinephrine,
so there is less vasoconstrictor in each injection. Less
vasoconstrictor is clearly more desirable and is consistent
with recommendations from the American Heart Association to use the
lowest available amount of vasoconstrictor.”
Mr. Mazzaro went on to say, “Orabloc is not only the first
aseptically manufactured Articaine available in the US, it is one
of the few Italian pharmaceutical products approved by FDA in the
last 30 years. The approval clearly shows the need and value of
Orabloc as its approval in the US is now joined by approvals in
Canada, Italy, and Russia with approvals pending in Germany, UK,
France, Austria, and Poland.”
According to Bernardo Verrengia, Scientific and Regulatory
Advisor for P
‘/>”/>
